0001209191-17-054197.txt : 20170927 0001209191-17-054197.hdr.sgml : 20170927 20170927214131 ACCESSION NUMBER: 0001209191-17-054197 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170925 FILED AS OF DATE: 20170927 DATE AS OF CHANGE: 20170927 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Wiezorek Jeffrey CENTRAL INDEX KEY: 0001610823 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36508 FILM NUMBER: 171105433 MAIL ADDRESS: STREET 1: C/O KITE PHARMA, INC. STREET 2: 2225 COLORADO AVENUE CITY: SANTA MONICA STATE: CA ZIP: 90404 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Kite Pharma, Inc. CENTRAL INDEX KEY: 0001510580 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE BUSINESS ADDRESS: STREET 1: 2225 COLORADO AVENUE CITY: SANTA MONICA STATE: CA ZIP: 90404 BUSINESS PHONE: (310) 824-9999 MAIL ADDRESS: STREET 1: 2225 COLORADO AVENUE CITY: SANTA MONICA STATE: CA ZIP: 90404 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2017-09-25 0 0001510580 Kite Pharma, Inc. KITE 0001610823 Wiezorek Jeffrey C/O KITE PHARMA, INC. 2225 COLORADO AVENUE SANTA MONICA CA 90404 0 1 0 0 SVP Clinical Development Common Stock 2017-09-25 4 A 0 10000 0.00 A 31107 D Common Stock 2017-09-25 4 S 0 5283 179.6639 D 25824 D Includes 36 shares acquired under the 2014 Employee Stock Purchase Plan on August 18, 2017. The shares were sold to cover the tax obligation that occurred upon the vesting of an RSU. /s/ David M. Tanen, Attorney-in-Fact 2017-09-27